Contributions
Abstract: EP1334
Type: ePoster
Abstract Category: Clinical aspects of MS - 5 Epidemiology
Background and goals: Epidemiologic studies have suggested an increasing temporal trend in the prevalence of multiple sclerosis (MS) across Asian countries. Nevertheless, the temporal trend in the disease activity of MS in these countries has not been fully evaluated yet.
Methods: One hundred seventy seven MS patients according to the international panel criteria
(112 females, mean age at onset of 30.7 ± 8.2 years) were retrospectively included from four MS-referral hospitals in Korea. The T2 lesion burden in brain MRI at disease onset was analyzed and clinical outcome after disease modifying treatment (DMT) was examined. The positive rate of oligoclonal band (OCB) by isoelectric focusing (IEF) method and the frequency of IgG index more than 0.67 were investigated for each birth year group.
Results: From the 1950s to the 1990s, the number of patients born in each decade was 4, 25, 65, 67, and 16, respectively. Patients born in more recent decade had a significantly higher number of T2 lesions (β=0.614 lesion per each year; 95% CI: 0.153-1.075; p=0.010) at disease onset. The birth year was a significant risk factor for relapses within 1 year and within 2 years after initiation of DMT (p = 0.020 and p = 0.001, respectively). The risk of clinical relapse within 2 years after DMT was 1.513 times higher when the birth year was delayed by 10 years (95% CI: 1.179-1.941; p=0.001). Onset age did not show a significant difference in terms of relapse risk. The positive rate of OCB and the proportion of raised IgG index > 0.67 tended to be higher in whom belong to a patient group of later born (p< 0.001 and p=0.003, respectively).
Conclusions: Our data imply that the disease activity of adult-onset MS patients in Korea is increasing over last five decades in terms of radiological and prognostic aspects. In addition, the patterns of CSF biomarkers have also been changing over time. This is a preliminary result from four MS-referral hospitals and further nationwide study is in progress.
Disclosure:
H.-J. Shin, W. Kim, S.-H. Baek, B.-J. Kim, J.-W. Hyun, S.-H. Kim, and S.-M. Kim have nothing to disclose.
H.J. Kim has lectured, consulted, and received honoraria from Bayer Schering Pharma, Biogen, Genzyme, HanAll BioPharma, MedImmune, Merck Serono, Novartis, Teva-Handok, and UCB; received a grant from the Ministry of Science, ICT and Future Planning; and accepted research funding from Genzyme, Kael-GemVax, Merck Serono, Teva-Handok, and UCB; serves on a steering committee for MedImmune; is a co-editor for the Multiple Sclerosis Journal - Experimental, Translational, and Clinical, and an associated editor for the Journal of Clinical Neurology.
Abstract: EP1334
Type: ePoster
Abstract Category: Clinical aspects of MS - 5 Epidemiology
Background and goals: Epidemiologic studies have suggested an increasing temporal trend in the prevalence of multiple sclerosis (MS) across Asian countries. Nevertheless, the temporal trend in the disease activity of MS in these countries has not been fully evaluated yet.
Methods: One hundred seventy seven MS patients according to the international panel criteria
(112 females, mean age at onset of 30.7 ± 8.2 years) were retrospectively included from four MS-referral hospitals in Korea. The T2 lesion burden in brain MRI at disease onset was analyzed and clinical outcome after disease modifying treatment (DMT) was examined. The positive rate of oligoclonal band (OCB) by isoelectric focusing (IEF) method and the frequency of IgG index more than 0.67 were investigated for each birth year group.
Results: From the 1950s to the 1990s, the number of patients born in each decade was 4, 25, 65, 67, and 16, respectively. Patients born in more recent decade had a significantly higher number of T2 lesions (β=0.614 lesion per each year; 95% CI: 0.153-1.075; p=0.010) at disease onset. The birth year was a significant risk factor for relapses within 1 year and within 2 years after initiation of DMT (p = 0.020 and p = 0.001, respectively). The risk of clinical relapse within 2 years after DMT was 1.513 times higher when the birth year was delayed by 10 years (95% CI: 1.179-1.941; p=0.001). Onset age did not show a significant difference in terms of relapse risk. The positive rate of OCB and the proportion of raised IgG index > 0.67 tended to be higher in whom belong to a patient group of later born (p< 0.001 and p=0.003, respectively).
Conclusions: Our data imply that the disease activity of adult-onset MS patients in Korea is increasing over last five decades in terms of radiological and prognostic aspects. In addition, the patterns of CSF biomarkers have also been changing over time. This is a preliminary result from four MS-referral hospitals and further nationwide study is in progress.
Disclosure:
H.-J. Shin, W. Kim, S.-H. Baek, B.-J. Kim, J.-W. Hyun, S.-H. Kim, and S.-M. Kim have nothing to disclose.
H.J. Kim has lectured, consulted, and received honoraria from Bayer Schering Pharma, Biogen, Genzyme, HanAll BioPharma, MedImmune, Merck Serono, Novartis, Teva-Handok, and UCB; received a grant from the Ministry of Science, ICT and Future Planning; and accepted research funding from Genzyme, Kael-GemVax, Merck Serono, Teva-Handok, and UCB; serves on a steering committee for MedImmune; is a co-editor for the Multiple Sclerosis Journal - Experimental, Translational, and Clinical, and an associated editor for the Journal of Clinical Neurology.